1. ZHAW digitalcollection
  2. Life Sciences und Facility Management
  3. Publikationen
  4. Publikationen Life Sciences und Facility Management
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWang, Z.-
dc.contributor.authorChen, C.-
dc.contributor.authorFinger, S. N.-
dc.contributor.authorKwajah M.M, S. d/o-
dc.contributor.authorJung, M.-
dc.contributor.authorSchwarz, H.-
dc.contributor.authorSwanson, N.-
dc.contributor.authorLareu, R. R.-
dc.contributor.authorRaghunath, M.-
dc.date.accessioned2018-10-26T14:29:29Z-
dc.date.available2018-10-26T14:29:29Z-
dc.date.issued2009-
dc.identifier.issn0903-1936de_CH
dc.identifier.issn1399-3003de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/12201-
dc.description.abstractPulmonary fibrosis represents a fatal stage of interstitial lung diseases of known and idiopathic aetiology. No effective therapy is currently available. Based on an indication-discovery approach we present novel in vitro evidence that the histone deacetylases inhibitor suberoylanilide hydroxamic acid (SAHA), an FDA approved anti-cancer drug, has antifibrotic and anti-inflammatory potential. Human lung fibroblasts (fetal, adult and idiopathic adult pulmonary fibrosis) were treated with transforming growth factor (TGF)-β1 with or without SAHA. Collagen deposition, α-smooth muscle actin (α-SMA) expression, matrix metalloproteinase (MMP)1 activity, tissue inhibitor of MMP (TIMP)1 production, apoptosis and cell proliferation were assessed. Pro-inflammatory cytokines relevant to pulmonary fibrosis were assayed in SAHA-treated human peripheral blood mononuclear cells (PBMC) and its subpopulations. SAHA abrogated TGF-β1 effects on all the fibroblast lines by preventing their transdifferentiation into α-SMA positive myofibroblasts and increased collagen deposition without inducing apoptosis. However, MMP1 activity and TIMP1 production was modulated without a clear fibrolytic effect. SAHA also inhibited serum-induced proliferation of the fibroblast lines and caused hyperacetylation of α-tubulin and histone. Cytokine secretion was inhibited from PBMC and lymphocytes at nonapoptotic concentrations. Taken together, these data demonstrate combined antifibrotic and anti-inflammatory properties of SAHA, suggesting its therapeutic potential for pulmonary fibrosis.de_CH
dc.language.isoende_CH
dc.publisherEuropean Respiratory Societyde_CH
dc.relation.ispartofThe European Respiratory Journalde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subject.ddc615: Pharmakologie und Therapeutikde_CH
dc.subject.ddc616: Innere Medizin und Krankheitende_CH
dc.titleSuberoylanilide hydroxamic acid : a potential epigenetic therapeutic agent for lung fibrosis?de_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementLife Sciences und Facility Managementde_CH
zhaw.organisationalunitInstitut für Chemie und Biotechnologie (ICBT)de_CH
dc.identifier.doi10.1183/09031936.00084808de_CH
zhaw.funding.euNode_CH
zhaw.issue1de_CH
zhaw.originated.zhawNode_CH
zhaw.pages.end155de_CH
zhaw.pages.start145de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume34de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.webfeedMetabolic Tissue Engineeringde_CH
Appears in collections:Publikationen Life Sciences und Facility Management

Files in This Item:
There are no files associated with this item.
Show simple item record
Wang, Z., Chen, C., Finger, S. N., Kwajah M.M, S. d., Jung, M., Schwarz, H., Swanson, N., Lareu, R. R., & Raghunath, M. (2009). Suberoylanilide hydroxamic acid : a potential epigenetic therapeutic agent for lung fibrosis? The European Respiratory Journal, 34(1), 145–155. https://doi.org/10.1183/09031936.00084808
Wang, Z. et al. (2009) ‘Suberoylanilide hydroxamic acid : a potential epigenetic therapeutic agent for lung fibrosis?’, The European Respiratory Journal, 34(1), pp. 145–155. Available at: https://doi.org/10.1183/09031936.00084808.
Z. Wang et al., “Suberoylanilide hydroxamic acid : a potential epigenetic therapeutic agent for lung fibrosis?,” The European Respiratory Journal, vol. 34, no. 1, pp. 145–155, 2009, doi: 10.1183/09031936.00084808.
WANG, Z., C. CHEN, S. N. FINGER, S. d/o KWAJAH M.M, M. JUNG, H. SCHWARZ, N. SWANSON, R. R. LAREU und M. RAGHUNATH, 2009. Suberoylanilide hydroxamic acid : a potential epigenetic therapeutic agent for lung fibrosis? The European Respiratory Journal. 2009. Bd. 34, Nr. 1, S. 145–155. DOI 10.1183/09031936.00084808
Wang, Z., C. Chen, S. N. Finger, S. d/o Kwajah M.M, M. Jung, H. Schwarz, N. Swanson, R. R. Lareu, and M. Raghunath. 2009. “Suberoylanilide Hydroxamic Acid : A Potential Epigenetic Therapeutic Agent for Lung Fibrosis?” The European Respiratory Journal 34 (1): 145–55. https://doi.org/10.1183/09031936.00084808.
Wang, Z., et al. “Suberoylanilide Hydroxamic Acid : A Potential Epigenetic Therapeutic Agent for Lung Fibrosis?” The European Respiratory Journal, vol. 34, no. 1, 2009, pp. 145–55, https://doi.org/10.1183/09031936.00084808.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.